KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Q3 2025 value amounting to $21.7 million.

  • Acadia Pharmaceuticals' Accounts Payables rose 1397.2% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 1397.2%. This contributed to the annual value of $16.2 million for FY2024, which is 770.11% down from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Accounts Payables stood at $21.7 million for Q3 2025, which was up 1397.2% from $20.1 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Accounts Payables registered a high of $21.7 million during Q3 2025, and its lowest value of $6.9 million during Q4 2021.
  • For the 5-year period, Acadia Pharmaceuticals' Accounts Payables averaged around $14.7 million, with its median value being $16.2 million (2024).
  • The largest annual percentage gain for Acadia Pharmaceuticals' Accounts Payables in the last 5 years was 12247.19% (2021), contrasted with its biggest fall of 1903.92% (2021).
  • Over the past 5 years, Acadia Pharmaceuticals' Accounts Payables (Quarter) stood at $6.9 million in 2021, then surged by 85.37% to $12.7 million in 2022, then surged by 37.64% to $17.5 million in 2023, then fell by 7.7% to $16.2 million in 2024, then soared by 34.31% to $21.7 million in 2025.
  • Its Accounts Payables was $21.7 million in Q3 2025, compared to $20.1 million in Q2 2025 and $18.1 million in Q1 2025.